12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cangrelor: Phase II data

The double-blind, international Phase II BRIDGE trial in 210 patients showed that 0.75 µg/kg/min IV cangrelor met the primary endpoint of a significantly greater proportion of patients who maintained target levels of platelet inhibition (<240 P2Y12 reaction units) for all time points measured between the end of thienopyridine therapy and the start of CABG vs. placebo (98.8% vs. 19%, p<0.0001). On the primary safety endpoint, there was no significant difference between cangrelor and placebo in the rate of...

Read the full 367 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >